Free Trial
NASDAQ:ONCY

Oncolytics Biotech Q2 2025 Earnings Report

Oncolytics Biotech logo
$1.08 -0.08 (-6.90%)
Closing price 09/4/2025 04:00 PM Eastern
Extended Trading
$1.13 +0.05 (+4.54%)
As of 09/4/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Oncolytics Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncolytics Biotech Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 8, 2025
Conference Call Time
10:00AM ET

Upcoming Earnings

Oncolytics Biotech's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Oncolytics Biotech Earnings Headlines

Retire Comfortably with These New Monthly Income ETFs?
Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.tc pixel
See More Oncolytics Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email.

About Oncolytics Biotech

Oncolytics Biotech (NASDAQ:ONCY), a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

View Oncolytics Biotech Profile

More Earnings Resources from MarketBeat